Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

The Lancet

Volumn 393, Issue 10167, 2019, Pages 156-167

  Cohen, Ezra E W ^a   Soulières, Denis ^b   Le Tourneau, Christophe ^c,d,e,s   Dinis, José ^f   Licitra, Lisa ^g,h,s   Ahn, Myung Ju ^i,s   Soria, Ainara ^j,s   Machiels, Jean Pascal ^k,l,s   Mach, Nicolas ^m,s   Mehra, Ranee ^n,s   Burtness, Barbara ^o   Zhang, Pingye ^p   Cheng, Jonathan ^p   Swaby, Ramona F ^p   Harrington, Kevin J ^q,r,s   Acosta Rivera, Mirelis ^s   Adkins, Douglas R ^s   Aghmesheh, Morteza ^s   Airoldi, Mario ^s   Aleknavicius, Eduardas ^s   Al Farhat, Yousuf ^s   Algazi, Alain P ^s   Almokadem, Salah ^s   Alyasova, Anna ^s   Bauman, Jessica R ^s   Benasso, Marco ^s   Berrocal, Alfonso ^s   Bray, Victoria ^s   Burtness, Barbara Ann ^s   Caponigro, Francesco ^s   Castro, Ana ^s   Cescon, Terrence P ^s   Chan, Kelvin ^s   Chaudhry, Arvind ^s   Chauffert, Bruno ^s   Cohen, Ezra ^s   Csoszi, Tibor ^s   De Boer, J P ^s   Delord, Jean Pierre ^s   Dietz, Andreas ^s   Dinis, Jose ^s   Dupuis, Charlotte ^s   Digue, Laurence ^s   Erfan, Jozsef ^s   Escobar Alvarez, Yolanda ^s   Evans, Mererid ^s   Fidler, Mary Jo ^s   Forster, Martin David ^s   Friesland, Signe ^s   Ganti, Apar K ^s   Geoffrois, Lionnel ^s   Grant, Cliona ^s   Gruenwald, Viktor ^s   Hoffmann, Thomas ^s   Horvai, Geza ^s   Inciura, Arturas ^s   Jang, Raymond ^s   Jankowska, Petra ^s   Jimeno, Antonio ^s   Joseph, Mano ^s   Juarez Ramiro, Alejandro ^s   Karaszewska, Boguslawa ^s   Kawecki, Andrzej ^s   Keilholz, Ulrich ^s   Keller, Ulrich ^s   Kim, Sung Bae ^s   Kocsis, Judit ^s   Kotecki, Nuria ^s   Kozloff, Mark F ^s   Lambea, Julio ^s   Landherr, Laszlo ^s   Lantsukhay, Yuri ^s   Lazarev, Sergey Alexandrovich ^s   Lee, Lip Way ^s   Lifirenko, Igor Dmitrievich ^s   Martincic, Danko ^s   Matorin, Oleg Vladmirovhich ^s   McGrath, Margaret ^s   Misiukiewicz, Krzysztof ^s   Morris, John C ^s   Mufazalov, Fagim Fanisovich ^s   Niu, Jiaxin ^s   Pamoorthy Srinivasan, Devraj ^s   Perez Segura, Pedro ^s   Rauch, Daniel ^s   Ribeiro, Maria Leonor ^s   Rodriguez, Cristina ^s   Rolland, Frederic ^s   Russo, Antonio ^s   Ruzsa, Agnes ^s   Sanches, Frederico ^s   Shin, Sang Won ^s   Shtiveland, Mikhail ^s   Soulieres, Denis ^s   Specenier, Pol ^s   Szekanecz, Eva ^s   Szota, Judit ^s   van Herpen, Carla M L ^s   Velez Cortes, Hector A ^s   Walsh, William V ^s   Wilop, Stefan ^s   Winterhalder, Ralph ^s   Wojtukiewicz, Marek ^s   Wong, Deborah ^s   Zandberg, Dan ^s   more..

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c INSTITUT CURIE   (France)

^d INSERM U900   (France)

^e LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^f PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ Samsung Medical Center   (South Korea)

^j HOSPITAL RAMÓN Y CAJAL   (Spain)

^k CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^l UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^m GENEVA UNIVERSITY HOSPITALS   (Switzerland)

ⁿ JOHNS HOPKINS UNIVERSITY   (United States)

^o YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p MERCK RESEARCH LABORATORIES   (United States)

^q INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^r INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^s NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DOCETAXEL; METHOTREXATE; PEMBROLIZUMAB; PLATINUM; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; COLITIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GUILLAIN BARRE SYNDROME; HAZARD RATIO; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEPATITIS; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INFUSION RELATED REACTION; INTENTION TO TREAT ANALYSIS; INTERACTIVE VOICE RESPONSE SYSTEM; INTERNET; LACK OF DRUG EFFECT; LARGE INTESTINE PERFORATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN ALLERGY; STEVENS JOHNSON SYNDROME; STOMATITIS; TREATMENT DURATION; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE EXACERBATION; DRUG ADMINISTRATION; HEAD AND NECK TUMOR; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; SECONDARY; TUMOR RECURRENCE;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CETUXIMAB; DISEASE PROGRESSION; DOCETAXEL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SQUAMOUS CELL CARCINOMA OF HEAD AND NECK;

EID: 85059907778     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)31999-8     Document Type: Article

References (27)

1. Licitra, L, Felip, E, Group, EGW, Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20:suppl 4 (2009), 121–122.
2. National Comprehensive Cancer Network I. NCCN clinical practice guidelines in oncology (NCCN guidelines): head and neck cancers, version 2. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf, 2018. (Accessed 2 August 2018)
3. Blanchard, P, Baujat, B, Holostenco, V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol 100 (2011), 33–40.
4. Vermorken, JB, Mesia, R, Rivera, F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359 (2008), 1116–1127.
5. Guardiola, E, Peyrade, F, Chaigneau, L, et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer 40 (2004), 2071–2076.
6. Vermorken, JB, Herbst, RS, Leon, X, Amellal, N, Baselga, J, Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer 112 (2008), 2710–2719.
7. Argiris, A, Ghebremichael, M, Gilbert, J, et al. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol 31 (2013), 1405–1414.
8. Seiwert, TY, Burtness, B, Mehra, R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 17 (2016), 956–965.
9. Chow, LQ, Haddad, R, Gupta, S, et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 34 (2016), 3838–3845.
10. Ferris, RL, Blumenschein, G Jr, Fayette, J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375 (2016), 1856–1867.
11. Moy, JD, Moskovitz, JM, Ferris, RL, Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. Eur J Cancer 76 (2017), 152–166.
12. Bauml, J, Seiwert, TY, Pfister, DG, et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J Clin Oncol 35 (2017), 1542–1549.
13. Bahleda, R, Braiteh, FS, Balmanoukian, AS, et al. Long-term safety and clinical outcomes of atezolizumab in head and neck cancer: phase Ia trial results. Ann Oncol, 28(suppl 5), 2017, 1044O.
14. Zandberg, D, Algazi, A, Jimeno, A, et al. Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): preliminary results from a single-arm, phase 2 study. Ann Oncol, 28(suppl 5), 2017, 1042O.
15. Eisenhauer, EA, Therasse, P, Bogaerts, J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009), 228–247.
16. Oken, MM, Creech, RH, Tormey, DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology group. Am J Clin Oncol 5 (1982), 649–655.
17. Efron, B, The efficiency of Cox's likelihood function for censored data. J Am Stat Assoc 72 (1977), 557–565.
18. Miettinen, O, Nurminen, M, Comparative analysis of two rates. Stat Med 4 (1985), 213–226.
19. Motzer, RJ, Escudier, B, McDermott, DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373 (2015), 1803–1813.
20. Herbst, RS, Baas, P, Kim, DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
21. Bellmunt, J, de Wit, R, Vaughn, DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376 (2017), 1015–1026.
22. Garon, EB, Rizvi, NA, Hui, R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
23. Hitt, R, Amador, ML, Quintela-Fandino, M, et al. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Cancer 106 (2006), 106–111.
24. Seiwert, TY, Cohen, EE, Haraf, DJ, et al. A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer. Cancer Invest 25 (2007), 435–444.
25. Camps, C, Massuti, B, Jimenez, A, et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol 17 (2006), 467–472.
26. Tannock, IF, de Wit, R, Berry, WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004), 1502–1512.
27. Ferris, RL, Blumenschein, G Jr, Fayette, J, et al. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 81 (2018), 45–51.